Business Wire

ISACA to Host Inaugural ISACA Conference Europe Virtual Event

Share

Next month, ISACA will host the first-ever ISACA Conference Europe, an event focused on emerging technologies, best practices, and leadership development. The conference will take place virtually 20-22 October featuring topics for business technology professionals as they navigate their transformational roles.

ISACA Conference Europe sessions range from 25-75 minutes in length and provide the opportunity to earn up to 19 continuing professional education credits. Conference tracks focus on IT audit, IT governance, COBIT, CMMI, cybersecurity, privacy, risk, performance improvement, emerging technologies, and leadership development & career management.

Sessions will be presented live via ISACA’s virtual conference platform, and many will feature a live Q&A with speakers. Attendees will have extended access to the sessions and content so they may view them at their own pace. Session topics include data ethics laws, blockchain, CMMI V2.0, cloud security, auditing artificial intelligence, quantum computing, privacy compliance, and much more.

Opening keynote speaker Dr. Beau Lotto, neuroscientist and world-renowned expert in perception, will share why trading certainty for doubt increases our capacity to adapt, lead, innovate, and thrive in the darkness of "I don’t know." Magician and entrepreneur Vinh Giang will use the themes of perspective, empowerment, goal setting, and positive mindset during his keynote to encourage attendees to believe in positive changes in their lives and business ventures. Shivvy Jervis, founder of the FutureScape 248 lab, will close the event with her keynote on the intersection of digital breakthroughs, scientific discoveries, and brain chemistry and how they can elevate business and our future.

One In Tech, an ISACA Foundation, will host a workshop, “Allies Required: Your Role in the Evolving Digital Trust Workforce,” which will discuss the importance of allies and advocates in advancing diversity, equity and inclusion within an organization. Participants will learn more about the role of an ally and how they can use the tools provided in the session to proactively and routinely champion inclusion.

ISACA Conference Europe encompasses topics previously found at ISACA events like CACS, CSX and Capability Counts. More details and registration for the conference can be found at https://www.isaca.org/conferences/isaca-conference-europe. Companies interested in participating as a sponsor can contact sponsorship@isaca.org.

ISACA has additional offerings this quarter, including:

  • Virtual Instructor-Led Training and Training Weeks
    • Advancing Your IT Auditing Skills, 20-24 September
    • Data Analytics and Visualization for Auditors, 27-30 September
    • IoT Fundamentals, 14-15 October
    • Privacy and Data Protection Simulation, 18-21 October
  • Training Week in New Orleans, LA, USA, 6-9 December, featuring exam preparation for CISM, CISA, Cybersecurity Fundamentals, and Data Science Fundamentals. This is an in-person event with safety practices in place: masks are required, and the classrooms will allow for optimized social distancing.
  • Free webinars on topics including securing hybrid environments, ISACA’s blockchain framework, building operational resilience, managing third-party risk, and active directory security.

ISACA will also host EVOLVE, its first-ever emerging tech conference, taking place virtually 16-17 November.

For more information, visit: https://www.isaca.org/training-and-events/.

About ISACA

For more than 50 years, ISACA® has equipped individuals with knowledge, credentials, education and community to progress their careers and transform their organizations, and enabled enterprises to train and build quality teams. ISACA leverages the expertise of its more than 150,000 members who work in information security, governance, assurance, risk and privacy to drive innovation through technology. It has a presence in 188 countries, including more than 220 chapters. In 2020, ISACA launched One In Tech, a philanthropic foundation.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Emily Van Camp, evcamp@isaca.org, +1.847.385.7223

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

NTT: CEOs Say People and the Planet Are Becoming More Important in Business18.10.2021 09:15:00 EEST | Press release

WSJ Intelligence undertook a new international CEO survey for global technology and business solution provider NTT. The survey focuses on the role of business in contributing to societal goals. WSJ Intelligence conducted a survey of 351 CEOs of large corporations representing ten key industries in 15 countries to understand their views on their organization’s role in society, social impact strategies, the stakeholders involved, and how the Covid-19 pandemic has driven these strategies. The research confirms that post-pandemic people and the planet rather than solely profit are becoming increasingly important for organizations of all sizes. While this trend was evident before March 2020, the pandemic brought it to the forefront. The latest research considers, too, how organizations better support employee wellbeing and change management. It uncovers the most valuable tools and tips for social purpose implementation while also analyzing the most significant challenges. Key Findings: 94%

"THE GUNPLA SHOWROOM DUBAI"18.10.2021 09:00:00 EEST | Press release

BANDAI SPIRITS Co., LTD. (President and Chief Executive Officer: Nao Udagawa, Head Office: Minato-ku, Tokyo) will be operating "THE GUNPLA SHOWROOM DUBAI" from late October, 2021 to March 31, 2022, at the Dubai Mall, a shopping mall in Dubai in the city of Dubai in the United Arab Emirates, concurrently with Expo 2020 Dubai that will begin on October 1, 2021. Given the appointment of Gundam as the "PR Ambassador of the Japan Pavilion, Expo 2020 Dubai", we will be promoting Japanese culture and the joy of monodukuri (creating and crafting) to people around the world through Gunpla (Gundam-series plastic models). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211017005004/en/ Display of 1/10 scale standing Gundam statue (Photo: Business Wire) Description of "THE GUNPLA SHOWROOM DUBAI" Exhibit of 1/10 Scale Standing Gundam Statue 1/10 scale standing statue of RX-78-2 (total height: approximately 1,800 mm) will be on exhibit. Lo

Antin Infrastructure Partners to Become Majority Shareholder in Origis Energy, a Leading U.S. Renewable Energy Platform18.10.2021 08:30:00 EEST | Press release

Regulatory News: Antin Infrastructure Partners (Ticker: ANTIN – ISIN: FR0014005AL0), one of the world’s leading infrastructure investment firms, announced today that funds managed by Antin have entered into a definitive agreement to acquire a majority stake in Origis Energy, a major vertically integrated renewable energy platform in the United States, from its CEO & President Guy Vanderhaegen and Global Atlantic Financial Group. The company focuses on developing, building, and operating utility-scale solar and storage assets, as well as distributed generation. Guy Vanderhaegen will continue to lead and to hold a significant stake in the company. Founded in 2008, Origis Energy has a track record of development success across 130 solar and storage projects. Antin will support Origis Energy with additional capital and resources as it builds out its contracted pipeline, which is one of the largest in the U.S. and provides clear visibility into its growth plan over the next several years. T

Ipsen Adds Another Program Into Its Pre-Clinical R&D Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, METTL318.10.2021 08:00:00 EEST | Press release

Regulatory News: Disclaimer: Intended for international media and investor audiences only Ipsen (Euronext: IPN; ADR: IPSEY) and Accent Therapeutics (Accent) have signed an exclusive worldwide-collaboration agreement to research, develop, manufacture, and commercialize Accent’s pre-clinical stage METTL3 program. Acute myeloid leukemia (AML) is a difficult to treat cancer of the blood and bone marrow, accounting for a third of all new cases of leukemia in the US each year.1 Globally, the incidence of AML has been increasing year on year across the last 20 years.2 RNA modifying proteins (RMPs) are an emerging target class that control multiple aspects of RNA biology and represent a new approach for the potential treatment of various cancers. METTL3 is an RMP that has been validated pre-clinically as a novel therapeutic target for AML.1,3 This collaboration combines Accent’s expertise in RMP-targeting therapeutics with Ipsen’s capabilities and proven track record in Oncology medicine devel

Nexign Completed Campaign Management Solution for Middle East Telecom Operator Zain Kuwait18.10.2021 08:00:00 EEST | Press release

Nexign (part of ICS Holding), an international provider of business support systems (BSS), has announced that the company completed the Marketing Campaign Management system implementation for Zain Kuwait, one of the leading telecom service providers in the Middle East, in cooperation with the Turkcell Technology, a subsidiary of Turkcell, a converged telecommunication and technology services provider, founded and headquartered in Turkey. The implemented system enables Zain Kuwait to provide targeted offerings to a wide range of its subscribers and boost customer loyalty and retention. Marketing Campaign Management System is a BI-integrated solution for diversified campaigns management during the customer lifecycle. It provides selection rules management to define target segments and communication channels to schedule, execute and track the performance of marketing campaigns. The system enables the company to increase response rates and make sales and marketing initiatives more effectiv

First-ever Winners of Prince William’s Earthshot Prize announced at star-studded London Awards Ceremony17.10.2021 23:00:00 EEST | Press release

The Earthshot Prize has tonight revealed the first-ever five Winners at a glittering ceremony held in London. Each Winner will receive £1million prize money and a global network of support to scale their cutting-edge environmental solutions to repair our planet. The five Winners, which span the globe from Costa Rica to India, include transformative technologists, innovators, an entire country, and a pioneering city and were chosen for their ground-breaking solutions to the greatest environmental challenges facing our planet. Earthshot Prize Founder and Prize Council Member Prince William said: “Our five inspirational Winners show that everyone has a role to play in the global effort to repair our planet. We need businesses, leaders, innovators, and communities to take action. And, ultimately, we need all of us to demand that the solutions get the support they need. Because the success of our Winners is our collective, global Earthshot.” Earthshot Prize Council Member Sir David Attenbor

Janssen Receives Positive CHMP Opinion for RYBREVANT® (amivantamab) for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations After Failure of Platinum-Based Therapy15.10.2021 19:30:00 EEST | Press release

FOR EU TRADE AND MEDICAL MEDIA ONLY. NOT TO BE DISTRIBUTED TO UK AND BENELUX BASED MEDIA The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product amivantamab, intended for the treatment of adult patients with advanced NSCLC with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations, after failure of platinum-based therapy.3 If approved, amivantamab will be the first treatment in the European Union specifically targeting EGFR exon 20 insertion mutations for advanced NSCLC.1 “This group of patients often face a poor prognosis as there are currently no targeted therapy options for this specific mutation nor does it typically respond to existing therapies used to treat more common EGFR mutations,” 1,4,5 commented Catherine Taylor, M.D., Vice President, Medical Affairs

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom